Oncotype Dx is a test that helps predict the chance of metastasis (when cancer spreads to other organs) for breast cancers that are:
It may also be used in select cases of lymph node-positive, estrogen receptor-positive breast cancer.
Oncotype Dx tests a sample of the tumor (removed during a biopsy or surgery) for a group of 21 genes. Along with other prognostic and diagnostic factors, the results of the Oncotype Dx test can be used to tailor treatment plans. If the test shows a person has a fairly high risk of metastasis, a more aggressive treatment plan that includes both hormone therapy and chemotherapy may be advised [32-33]. If the test shows a low risk of recurrence, the use of hormone therapy alone may be considered.
Active areas of study
Oncotype Dx is under study for use in lymph node-positive, estrogen receptor-positive breast cancers [34-35]. Researchers are also studying whether it can predict how well other breast cancers will respond to different chemotherapy drugs.
Updated 10/26/12
